Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 275Lung Neoplasms 106Adenocarcinoma of Lung 27Mesothelioma, Malignant 22Neoplasms 19Neoplasm Metastasis 18Breast Neoplasms 13Brain Neoplasms 13Mesothelioma 10Head and Neck Neoplasms 10Ovarian Neoplasms 8Colorectal Neoplasms 8Recurrence 7Adenocarcinoma, Bronchiolo-Alveolar 7Small Cell Lung Carcinoma 6NSCLC 6Adenocarcinoma 6Parkinson Disease 4, Autosomal Dominant Lewy Body 5Meningeal Carcinomatosis 5Carcinoma 5Urinary Bladder Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Solitary Fibrous Tumor, Pleural 4Sarcoma 4Pancreatic Neoplasms 4Non-small Cell Lung Cancer Metastatic 4Laryngeal Diseases 4Carcinoma, Transitional Cell 4Uterine Neoplasms 3Uterine Cervical Neoplasms 3

Interventions

Docetaxel 5S 1 (combination) 2Carboplatin 2zimberelimab 1surufatinib 1quemliclustat 1pemigatinib 1nimotuzumab 1lorlatinib 1cemiplimab 1Vinorelbine 1Pemetrexed 1Paclitaxel 1Gene Expression Profiling 1Gemcitabine 1Erlotinib Hydrochloride 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Advanced Non-Small Cell Lung Cancer × Pemetrexed × Clear all
NCT00786331 2009-08-03

Pemetrexed +/- Carboplatin as Second Line Treatment in NSCLC

Gruppo Oncologico Italiano di Ricerca Clinica

Phase 2 Unknown
230 enrolled
Thoracic

Advanced Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡